Bsw Wealth Partners Exits Position in Regeneron Pharmaceuticals Inc (REGN)

Regeneron Pharmaceuticals Inc (REGN) : Bsw Wealth Partners has sold out all of its stake in Regeneron Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Aug 11, 2016 with the SEC. The investment management company has sold out 684 shares of Regeneron Pharmaceuticals Inc which is valued at $288,333.

Other Hedge Funds, Including , Alliancebernstein reduced its stake in REGN by selling 1,779 shares or 0.72% in the most recent quarter. The Hedge Fund company now holds 244,984 shares of REGN which is valued at $103,270,555. Regeneron Pharmaceuticals Inc makes up approx 0.09% of Alliancebernstein’s portfolio.Dekabank Deutsche Girozentrale boosted its stake in REGN in the latest quarter, The investment management firm added 97 additional shares and now holds a total of 64,519 shares of Regeneron Pharmaceuticals Inc which is valued at $27,291,537. Regeneron Pharmaceuticals Inc makes up approx 0.30% of Dekabank Deutsche Girozentrale’s portfolio.Cibc Asset Management Inc boosted its stake in REGN in the latest quarter, The investment management firm added 175 additional shares and now holds a total of 11,388 shares of Regeneron Pharmaceuticals Inc which is valued at $5,026,322. Regeneron Pharmaceuticals Inc makes up approx 0.04% of Cibc Asset Management Inc’s portfolio.Proficio Capital Partners reduced its stake in REGN by selling 2 shares or 1.65% in the most recent quarter. The Hedge Fund company now holds 119 shares of REGN which is valued at $50,589. Regeneron Pharmaceuticals Inc makes up approx 0.03% of Proficio Capital Partners’s portfolio.Mu Investments Ltd. reduced its stake in REGN by selling 170 shares or 36.96% in the most recent quarter. The Hedge Fund company now holds 290 shares of REGN which is valued at $120,376. Regeneron Pharmaceuticals Inc makes up approx 0.08% of Mu Investments Ltd.’s portfolio.

Regeneron Pharmaceuticals Inc opened for trading at $420.15 and hit $424.999 on the upside on Tuesday, eventually ending the session at $420.61, with a gain of 0.47% or 1.96 points. The heightened volatility saw the trading volume jump to 4,52,160 shares. Company has a market cap of $44,288 M.

On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.

Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.

Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *